Xiaodong Wang

US Patent:

6346607, Feb 12, 2002

Filed:

Nov 5, 1999

Appl. No.:

09/435115

Inventors:

Xiaodong Wang - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07K 1400

US Classification:

530350, 530409, 435183, 435 4

Abstract:

Novel polypeptides, designated Apaf-1, which are capable of modulating apoptosis are provided. Compositions including Apaf-1 chimeras, nucleic acid encoding Apaf-1, and antibodies to Apaf-1 are also provided.

US Patent:

6515118, Feb 4, 2003

Filed:

Apr 17, 1997

Appl. No.:

08/842760

Inventors:

Xiaodong Wang - Dallas TX
Xuesong Liu - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 2102

US Classification:

536 231, 435 69 T, 4355201, 435325

Abstract:

The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridizing with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

US Patent:

6534267, Mar 18, 2003

Filed:

Jul 28, 2000

Appl. No.:

09/627393

Inventors:

Xiaodong Wang - Dallas TX 75235-9038
Chunying Du - Dallas TX 75235-9050

International Classification:

C12Q 168

US Classification:

435 6, 536 231, 536 232, 536 235

Abstract:

The invention provides methods and compositions relating to human polypeptide activators of caspases such as polypeptide and polynucleotide sequences diagnostic of caspase activators. These sequences and polypeptides and polynucleotides embodying these sequences find a wide vanety of diagnostic and therapeutic applications involving detecting and/or modulating expression and/or function of activators or caspases or genes or transcripts encoding such activators and generating genetic and immuno probes specific to activators of caspases.

US Patent:

6558900, May 6, 2003

Filed:

Jul 11, 1997

Appl. No.:

08/891525

Inventors:

Xiaodong Wang - Dallas TX
Xuesong Liu - Dallas TX

Assignee:

Emory University - Atlanta GA

International Classification:

C12Q 168

US Classification:

435 6, 435 71, 435 723, 435 74, 435 792, 435 23, 436 63, 436 64

Abstract:

A cell-free system based on the cytosol of normally growing cells, which reproduces measurable aspects of the apoptotic program, is provided. The apoptotic program is initiated by addition of DATP in the specific exemplification of the HeLa 100,000Ãg supernatant. Fractionation of the cytosol yielded a 15 kDa protein, identified by absorption spectrum and protein sequence as cytochrome c, that is required for in vitro apoptosis. Elimination of cytochrome c from cytosol by immunodepletion or inclusion of sucrose to stabilize mitochondria during cytosol preparation, diminished the apoptotic activity. Addition of exogenous cytochrome c to cytochrome c-depleted extracts restored apoptotic activity. Cells undergoing apoptosis in vivo showed increased release of cytochrome c to their cytosol, suggesting that mitochondria may function in apoptosis by releasing cytochrome c.

US Patent:

6608026, Aug 19, 2003

Filed:

Aug 23, 2000

Appl. No.:

09/645075

Inventors:

Xiaodong Wang - Dallas TX
Chunying Du - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A01N 3718

US Classification:

514 2, 530300

Abstract:

The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX , wherein X is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX , wherein X is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis. The invention also provides assays for identifying agents which modulates the interaction of an AV peptoid with an IAP, active compounds identified in such screens and their use in the foregoing compositions and therapeutic methods.

US Patent:

6725025, Apr 20, 2004

Filed:

Sep 20, 2000

Appl. No.:

09/665843

Inventors:

Timothy M. Schmidl - Dallas TX
Alan Gatherer - Richardson TX
Xiaodong Wang - College Station TX
Rong Chen - Chicago IL

Assignee:

Texas Instruments Incorporated - Dallas TX

International Classification:

H04B 106

US Classification:

4552781, 455295, 455296

Abstract:

An improved interference cancellation technique is disclosed. Digital baseband circuitry ( ) includes user and symbol detection circuitry ( ) for performing a Gibbs sampler type of interference cancellation, either embodied in custom hardware ( ) or in software. Random initial guesses for a signal sample (either a symbol or chip) are made for each user. Interference cancellation is performed on a user-by-user basis, using the then-current data decision values for the other, interfering users. A soft data decision is used to derive a probability distribution function for the actual data decision for the sample for the user. A randomly selected value is applied against the probability distribution function to generate the next data decision value for that user, and the process is repeated until convergence. Following convergence, a statistic is used to select a final data decision value for each user, from the set of intermediate data decision values stored in memory.

US Patent:

6790648, Sep 14, 2004

Filed:

Dec 22, 2000

Appl. No.:

09/748451

Inventors:

Xiaodong Wang - Dallas TX
Xuesong Liu - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 922

US Classification:

435196, 530300, 530321, 530326, 435 691, 4352523, 4353201, 536 232

Abstract:

The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polypeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF, hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

US Patent:

7041784, May 9, 2006

Filed:

Aug 15, 2003

Appl. No.:

10/641539

Inventors:

Xiaodong Wang - Dallas TX, US
Chunying Du - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 38/00

US Classification:

530300, 530317, 530326

Abstract:

The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX, wherein Xis V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX, wherein Xis V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis. The invention also provides assays for identifying agents which modulates the interaction of an AV peptoid with an IAP, active compounds identified in such screens and their use in the foregoing compositions and therapeutic methods.